Current landscape of targeted therapy in lung cancer MK Mayekar, TG Bivona Clinical Pharmacology & Therapeutics 102 (5), 757-764, 2017 | 163 | 2017 |
Structural basis for Spt5-mediated recruitment of the Paf1 complex to chromatin AD Wier, MK Mayekar, A Héroux, KM Arndt, AP VanDemark Proceedings of the National Academy of Sciences 110 (43), 17290-17295, 2013 | 106 | 2013 |
C/EBPγ Is a Critical Regulator of Cellular Stress Response Networks through Heterodimerization with ATF4 PFJ Christopher J Huggins, Manasi K Mayekar, Nancy Martin, Karen L Saylor ... Molecular and cellular biology 36 (5), 693-713, 2016 | 98 | 2016 |
The Recruitment of the Saccharomyces cerevisiae Paf1 Complex to Active Genes Requires a Domain of Rtf1 That Directly Interacts with the Spt4-Spt5 Complex MK Mayekar, RG Gardner, KM Arndt Molecular and cellular biology 33 (16), 3259-3273, 2013 | 69 | 2013 |
Small region of Rtf1 protein can substitute for complete Paf1 complex in facilitating global histone H2B ubiquitylation in yeast AS Piro, MK Mayekar, MH Warner, CP Davis, KM Arndt Proceedings of the National Academy of Sciences 109 (27), 10837-10842, 2012 | 69 | 2012 |
Differential subcellular localization regulates oncogenic signaling by ROS1 kinase fusion proteins DS Neel, DV Allegakoen, V Olivas, MK Mayekar, G Hemmati, ... Cancer research 79 (3), 546-556, 2019 | 65 | 2019 |
Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer S Nanjo, W Wu, N Karachaliou, CM Blakely, J Suzuki, YT Chou, SM Ali, ... The Journal of clinical investigation 132 (13), 2022 | 23 | 2022 |
Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G CW Liu Jia, Mayekar Manasi K, Wu Wei, Yan Ming, Guan Hongya, Wang Jinwu ... Cancer Letters, 2020 | 21 | 2020 |
Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistance BioRxiv, 2020 | 18* | 2020 |
Synthetic essentiality of metabolic regulator PDHK1 in PTEN-deficient cells and cancers N Chatterjee, E Pazarentzos, MK Mayekar, P Gui, DV Allegakoen, ... Cell reports 28 (9), 2317-2330. e8, 2019 | 18 | 2019 |
Betacellulin drives therapy resistance in glioblastoma QW Fan, Z An, RA Wong, X Luo, ED Lu, A Baldwin, MK Mayekar, ... Neuro-oncology 22 (4), 457-469, 2020 | 11 | 2020 |
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance DR Caswell, P Gui, MK Mayekar, EK Law, O Pich, C Bailey, J Boumelha, ... Nature Genetics 56 (1), 60-73, 2024 | 9 | 2024 |
The role of APOBEC3B in lung tumour evolution and targeted therapy resistance DR Caswell, MK Mayekar, P Gui, EK Law, NI Vokes, CM Ruiz, M Dietzen, ... bioRxiv, 2020.12. 18.423280, 2020 | 2 | 2020 |
Abstract LB124: APOBEC3B fuels evolution of resistance during targeted cancer therapy MK Mayekar, D Caswell, N Vokes, W Wu, C McCoach, C Blakely, ... Cancer Research 81 (13_Supplement), LB124-LB124, 2021 | | 2021 |
APOBEC3B and TKI resistance in EGFR mutant lung cancer D Caswell, M Mayekar, E Law, W Hill, E Gronroos, R Harris, T Bivona, ... Cancer Research 81 (13_Supplement), 2938-2938, 2021 | | 2021 |
B15 COP1 E3 Ligase Modulates Response to Oncogenic MAPK Pathway Inhibition MK Mayekar, L Lin, TG Bivona Journal of Thoracic Oncology 15 (2), S32, 2020 | | 2020 |
Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. E Pazarentzos, M Mayekar, P Gui, D Allegakoen, G Hrustanovic, V Olivas, ... Cell Reports 28 (9), 2019 | | 2019 |
COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition MK Mayekar, L Lin, TG Bivona Cancer Research 78 (13_Supplement), 920-920, 2018 | | 2018 |
Abstract LB-124: COP1 E3 ligase modulates response to oncogenic MAPK pathway inhibition MK Mayekar, T Bivona Cancer Research 77 (13_Supplement), LB-124-LB-124, 2017 | | 2017 |
Abstract PR02: C/EBPG: A critical stress response regulator with a pro-oncogenic role MK Mayekar, CJ Huggins, N Martin, KL Saylor, M Gonit, P Jailwala, ... Cancer Research 76 (3_Supplement), PR02-PR02, 2016 | | 2016 |